10x Genomics (TXG) Cash & Current Investments (2018 - 2026)

10x Genomics has disclosed Cash & Current Investments across 9 years of filings, most recently posting $552.0 million for Q2 2026.

• In Q2 2026, Cash & Current Investments rose 23.43% year-over-year to $552.0 million; the TTM figure through Jun 2026 stood at $552.0 million (up 23.43% YoY), while the FY2025 annual figure was $523.4 million, up 33.05% from the prior year.
• Cash & Current Investments came in at $552.0 million for Q2 2026 at 10x Genomics, up from $539.8 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $552.0 million in Q2 2026 to a low of $356.9 million in Q3 2023.
• Average Cash & Current Investments over 5 years is $444.0 million, with a median of $428.4 million recorded in 2022.
• Year-over-year, Cash & Current Investments fell 26.93% in 2022 and surged 33.05% in 2025.
• Over 5 years, Cash & Current Investments stood at $430.0 million in 2022, then fell by 9.6% to $388.7 million in 2023, then grew by 1.21% to $393.4 million in 2024, then soared by 33.05% to $523.4 million in 2025, then rose by 5.47% to $552.0 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $552.0 million in Q2 2026, $539.8 million in Q1 2026, and $523.4 million in Q4 2025.